Shandong Quanzhong Biopharmaceutical

Shandong Quanzhong Biopharmaceutical is a China-based biotechnology company dedicated to the development and commercialization of long-acting recombinant protein and peptide therapeutics. The company leverages its proprietary PEGylation technology platform to create bio-better drugs with improved pharmacokinetic profiles and reduced dosing frequency. Its clinical pipeline features several advanced candidates, including long-acting versions of G-CSF for neutropenia and growth hormone for pediatric deficiency, both of which have reached late-stage clinical trials. Headquartered in Jinan, the company maintains integrated R&D and GMP-compliant manufacturing capabilities to support its mission of providing high-quality biologics. Shandong Quanzhong Biopharmaceutical focuses primarily on therapeutic areas such as oncology, endocrinology, and infectious diseases within the Chinese market.